HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Has Slim Boost For FDA FY2023 Spending, But Wants Slimmer Budget Document From Agency

Executive Summary

Appropriations Committee publishes FY2023 spending bill and report FDA day before it votes on the legislation. It recommends increasing FDA’s budget by less than $400m from its current appropriation to $6.48bn.

You may also be interested in...



US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

House Appropriation Leaders Propose Emergency Funding For FDA's Infant Formula Programs

Democrats introduce bill two days before Agriculture, Rural Development, FDA and Related Agencies subcommittee will question FDA Commissioner Robert Califf about agency’s oversight of formula industry during a hearing on FY2023 budget.

OTC Monograph User Fees Grow In FDA FY2023 Budget Request And In Industry's Thinking

Stakeholders didn’t indicate extensive familiarity with OTC monograph user fees during online workshop. Biden administration’s FDA FY2023 budget request includes $5m increase to $30.36m in facility registration fees required from all firms manufacturing OTC monograph drugs available in US.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152653

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel